Cabenuva (Cabotegravir/Rilpivirine) for HIV

Overview
Cabenuva is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with HIV-1 infection. Cabenuva is indicated as a complete treatment regimen. Cabenuva is used as a therapy for HIV-1 infection. Cabenuva is a combination of two drugs, cabotegravir and rilpivirine, that work together to prevent the HIV-1 virus from replicating inside body cells. Cabenuva is believed to work by interfering with viral DNA replication.

How do I take it?
Prescribing information states that Cabenuva is given as intramuscular injection by a health care professional.

Cabenuva is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by your doctor. Cabenuva is available only as an intramuscular injection.

Side effects
The FDA-approved label for Cabenuva lists common side effects that include injection site reactions; fever; fatigue; headache; pain in the muscles, bones, ligaments, tendons, or nerves; nausea; sleep disorders; dizziness; and rash. Serious side effects listed for Cabenuva include hypersensitivity reactions, serious post-injection reactions, liver damage, and symptoms of depression.

For more details about this treatment, visit:

Cabenuva – ViiV Healthcare

FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV – U.S. Food and Drug Administration